Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial

Abstract

Background: Pyronaridine-artesunate is a novel artemisinin-based combination therapy. The efficacy and safety of pyronaridine-artesunate were compared with artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children.

Methods: This phase III open-label randomized controlled non-inferiority trial was conducted in Western Kenya. Children aged 6 months to ≤ 12 years with a bodyweight > 5 kg and microscopically confirmed P. falciparum malaria were randomly assigned in a 1:1 ratio to orally receive pyronaridine-artesunate or artemether-lumefantrine, dosed according to bodyweight, for 3 days.

Results: Of 197 participants, 101 received pyronaridine-artesunate and 96 received artemether-lumefantrine. The day-28 adequate clinical and parasitological response in the per-protocol population, PCR-corrected for reinfections, was 98.9% (93/94, 95% CI 94.2-99.8) for pyronaridine-artesunate and 96.4% (81/84, 95% CI 90.0-98.8) for artemether-lumefantrine. Pyronaridine-artesunate was found to be non-inferior to artemether-lumefantrine: the treatment difference was 2.5% (95% CI - 2.8 to 9.0). Adverse events occurred in 41.6% (42/101) and 34.4% (33/96) of patients in the pyronaridine-artesunate group and the artemether-lumefantrine group, respectively. No participants were found to have alanine or aspartate aminotransferase levels > 3 times the upper limit of normal.

Conclusions: Pyronaridine-artesunate was well tolerated, efficacious and non-inferior to artemether-lumefantrine for the treatment of uncomplicated P. falciparum malaria in Kenyan children. Results are in line with previous reports and inclusion of pyronaridine-artesunate in paediatric malaria treatment programmes should be considered. This study is registered at clinicaltrials.gov under NCT02411994. Registration date: 8 April 2015. https://ichgcp.net/clinical-trials-registry/NCT02411994?term=pyronaridine-artesunate&cond=Malaria&cntry=KE&rank=1.

Keywords: Artemether–lumefantrine; Kenya; Malaria; Paediatric; Plasmodium falciparum; Pyronaridine–artesunate.

Figures

Fig. 1

Participant flow. Number of patients screened, randomized and included in the per-protocol population. Some patients had more than one reason for exclusion from the per-protocol population

Fig. 2

Kaplan–Meier estimates for a rate of recrudescence and b rate of reinfection (in the intention-to-treat population). Black markers represent censored cases. Participants without the event (recrudescence or reinfection) were censored at the last available parasite assessment date

Fig. 3

Kaplan–Meier estimates for a time to parasite clearance (intention-to-treat population) and b time to fever clearance. Participants without the event (parasite or fever clearance) were censored at the last available parasite or fever assessment date